Login Register Cart 0
Generic placeholder image

Current Reviews in Clinical and Experimental Pharmacology

Editor-in-Chief

ISSN (Print): 2772-4328
ISSN (Online): 2772-4336

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Systematic Review Article

A Systematic Review of Randomized Clinical Trials on the Efficacy and Safety of Pitavastatin

Author(s): Adel Sadeq, Asim Ahmed Elnour*, Farah Hamad Farah, Azza Ramadan, Mohamed A. Baraka, Judit Don, Abdulla Al Amoodi, Kishore Gnana Sam, Nadia Al Mazrouei and Maisoun Alkaabi

Volume 18, Issue 2, 2023

Published on: 16 September, 2022

Page: [120 - 147] Pages: 28

DOI: 10.2174/2772432817666220531115314

Price: $65

Abstract

Background: A subpopulation of statin users such as subjects with chronic kidney disease (CKD), Human Immune virus (HIV), acute coronary syndrome (ACS), revascularization, metabolic syndrome, and/or diabetes may particularly benefit from pitavastatin pharmacotherapy.

Aim: The current systematic review aimed systematically to evaluate the effect of pitavastatin on primary cardiac events in subjects receiving pitavastatin in comparison to the other four statin members.

Methods: We conducted a systematic review on phases III and IV of randomized controlled trials (RCT-s, 11 trials) for subjects with primary cardiac events who received pitavastatin. Subjects diagnosed with any type of dyslipidemia (population 4804) and received pitavastatin (interventions) versus comparator (comparison) with the primary efficacy endpoint of minimization of LDL-C and non- HDL-C, had an increase in HDL-C and/or reduction in major adverse cardiac events (MACE, cardiovascular death, myocardial infarction (fatal/nonfatal), and stroke (fatal/nonfatal) and/or their composite (outcomes). The secondary safety endpoint was the development of any adverse effects.

Results: In the included trials (11), participants (4804) were randomized for pitavastatin or its comparators such as atorvastatin, pravastatin, rosuvastatin, simvastatin and followed up for 12 to 52 weeks. In terms of the primary outcome (reduction in LDL-C), pitavastatin 4 mg was superior to pravastatin 40 mg in three trials, while the 2 mg pitavastatin was comparable to atorvastatin 10 mg in four trials and simvastatin 20 and 40 mg in two 2 trials. However, rosuvastatin 2.5 mg was superior to pitavastatin 2 mg in two trials. Pitavastatin increased HDL-C and reduced non-HDL-C in eleven trials. Regarding the safety profile, pitavastatin has proved to be tolerated and safe.

Conclusion: The FDA-approved indications for pitavastatin included primary dyslipidemia and mixed dyslipidemia as a supplementary therapy to dietary changes to lower total cholesterol, LDL-C, apolipoprotein B (Apo B), triglycerides (TG), and enhance HDL-C. Pitavastatin might be suitable for subjects with diabetes, ACS (reduced revascularization), metabolic syndrome, CKD, HIV, and subjects with low levels of HDL-C. We highly recommend rational individualization for the selection of statin.

Keywords: Dyslipidemia, efficacy, low-density lipoprotein cholesterol (LDL-C), pitavastatin, randomized clinical trial, safety.

« Previous Next »
Graphical Abstract

[1]
Kurihara Y, Douzono T, Kawakita K, Nagasaka Y. A large-scale, long-term prospective post-marketing surveillance of pitavastatin (Livalo) – Livalo effectiveness and safety study (LIVES). Jpn Pharmacol Ther 2008; 36(8): 709-31.
[2]
Budinski D, Arneson V, Hounslow N, Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol 2009; 4(3): 291-302.
[http://dx.doi.org/10.2217/clp.09.20]
[3]
Huang CH, Huang YY, Hsu BRS. Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes. J Diabetes Investig 2016; 7(5): 769-76.
[http://dx.doi.org/10.1111/jdi.12483] [PMID: 27181110]
[4]
Sakabe K, Fukuda N, Fukuda Y, et al. Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function. IJC 2008; 125(1): 136-8.
[http://dx.doi.org/10.1016/j.ijcard.2007.01.040] [PMID: 17400311]
[5]
Gumprecht J, Gosho M, Budinski D, Hounslow N. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab 2011; 13(11): 1047-55.
[http://dx.doi.org/10.1111/j.1463-1326.2011.01477.x] [PMID: 21812889]
[6]
Mita T, Nakayama S, Abe H, et al. Comparison of effects of pitavastatin and atorvastatin on glucose metabolism in type 2 diabetic patients with hypercholesterolemia. J Diabetes Investig 2013; 4(3): 297-303.
[http://dx.doi.org/10.1111/jdi.12032] [PMID: 24843669]
[7]
Choi JY, Choi CU, Hwang SY, et al. Effect of pitavastatin compared with atorvastatin androsuvastatin on new-onset diabetes mellitus in patients with acute myocardial infarction. Am J Cardiol 2018; 122(6): 922-8.
[http://dx.doi.org/10.1016/j.amjcard.2018.06.017] [PMID: 30217375]
[8]
Poolsup N, Suksomboon N, Wongyaowarat K, Rungkanchananon B, Niyomrat P, Kongsuwan S. Meta-analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia. J Clin Pharm Ther 2012; 37(2): 166-72.
[http://dx.doi.org/10.1111/j.1365-2710.2011.01274.x] [PMID: 21585411]
[9]
Liu WT, Lin C, Tsai MC, et al. Effects of pitavastatin, atorvastatin, and rosuvastatin on the risk of new-onset diabetes mellitus: A single-center cohort study. Biomedicines 2020; 8(11): 499.
[http://dx.doi.org/10.3390/biomedicines8110499] [PMID: 33202854]
[10]
Adel Sadeq AA. Protocol for systematic review and meta-analysis on randomized clinical trials on the efficacy and safety of pitavastatin. Sys Rev Pharm 2020; 11(12): 2333-42.
[11]
Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 4(1): 1.
[http://dx.doi.org/10.1186/2046-4053-4-1] [PMID: 25554246]
[12]
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996; 17(1): 1-12.
[http://dx.doi.org/10.1016/0197-2456(95)00134-4] [PMID: 8721797]
[13]
Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011; 64(4): 401-6.
[http://dx.doi.org/10.1016/j.jclinepi.2010.07.015] [PMID: 21208779]
[14]
Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64(4): 383-94.
[http://dx.doi.org/10.1016/j.jclinepi.2010.04.026] [PMID: 21195583]
[15]
Morgan RL, Thayer KA, Bero L, et al. GRADE: Assessing the quality of evidence in environmental and occupational health. Environ Int 2016; 92-93: 611-6.
[http://dx.doi.org/10.1016/j.envint.2016.01.004] [PMID: 26827182]
[16]
Moroi M, Nagayama D, Hara F, et al. Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease. Int J Cardiol 2020; 305: 139-46.
[http://dx.doi.org/10.1016/j.ijcard.2020.01.006] [PMID: 31987664]
[17]
Aberg JA, Sponseller CA, Ward DJ, Kryzhanovski VA, Campbell SE, Thompson MA. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial. Lancet HIV 2017; 4(7): e284-94.
[http://dx.doi.org/10.1016/S2352-3018(17)30075-9] [PMID: 28416195]
[18]
Abe M, Maruyama N, Maruyama T, Okada K, Soma M. A trial of pitavastatin versus rosuvastatin for dyslipidemia in chronic kidney disease. J Atheroscler Thromb 2015; 22(12): 1235-47.
[http://dx.doi.org/10.5551/jat.29264] [PMID: 26156625]
[19]
Sponseller CA, Morgan RE, Kryzhanovski VA, Campbell SE, Davidson MH. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: A Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial. Clin Ther 2014; 36(8): 1211-22.
[http://dx.doi.org/10.1016/j.clinthera.2014.06.009] [PMID: 24998014]
[20]
Kurogi K, Sugiyama S, Sakamoto K, et al. Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: The COMPACT-CAD study. J Cardiol 2013; 62(2): 87-94.
[http://dx.doi.org/10.1016/j.jjcc.2013.03.008] [PMID: 23672789]
[21]
Stender S, Budinski D, Gosho M, Hounslow N. Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. Eur J Prev Cardiol 2013; 20(1): 40-53.
[http://dx.doi.org/10.1177/2047487312451251] [PMID: 22679249]
[22]
Saku K, Zhang B, Noda K. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): The PATROL trial. Circ J 2011; 75(6): 1493-505.
[http://dx.doi.org/10.1253/circj.CJ-10-1281] [PMID: 21498906]
[23]
Ose L, Budinski D, Hounslow N, Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin 2009; 25(11): 2755-64.
[http://dx.doi.org/10.1185/03007990903290886] [PMID: 19785568]
[24]
Yokote K, Bujo H, Hanaoka H, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: Collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis 2008; 201(2): 345-52.
[http://dx.doi.org/10.1016/j.atherosclerosis.2008.02.008] [PMID: 18472103]
[25]
Park S, Kang HJ, Rim SJ, et al. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia. Clin Ther 2005; 27(7): 1074-82.
[http://dx.doi.org/10.1016/j.clinthera.2005.07.007] [PMID: 16154486]
[26]
Ogiso M, Yamaguchi J, Kawada-Watanabe E, et al. Effect of aggressive lipid-lowering therapy in single-vessel vs. multivessel coronary artery disease patients with acute coronary syndrome?? Heart institute of japan-proper level of lipid lowering with pitavastatin and ezetimibe in acute coronary syndrome (HIJ-PROPER) substudy. Circ Rep 2020; 2(2): 128-34.
[http://dx.doi.org/10.1253/circrep.CR-19-0118] [PMID: 33693218]
[27]
Taguchi I, Iimuro S, Iwata H, et al. High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD): A randomized superiority trial. Circulation 2018; 137(19): 1997-2009.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.117.032615] [PMID: 29735587]
[28]
Teramoto T, Shimano H, Yokote K, Urashima M. Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. J Atheroscler Thromb 2009; 16(5): 654-61.
[http://dx.doi.org/10.5551/jat.1719] [PMID: 19907105]
[29]
Nomura S, Shouzu A, Omoto S, et al. Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus. Thromb Res 2008; 122(1): 39-45.
[http://dx.doi.org/10.1016/j.thromres.2007.08.013] [PMID: 17920663]
[30]
Saito Y, Yamada N, Teramoto T, et al. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison. Arzneimittelforschung 2002; 52(4): 251-5.
[http://dx.doi.org/10.1055/s-0031-1299888] [PMID: 12040967]
[31]
Yamazaki T, Kishimoto J, Ito C, Noda M, Odawara M, Kadowaki T. Japan prevention trial of diabetes by pitavastatin in patients with impaired glucose tolerance (the J-PREDICT study): Rationale, study design, and clinical characteristics of 1269 patients. Diabetol Int 2011; 2(3): 134-40.
[http://dx.doi.org/10.1007/s13340-011-0032-0]
[32]
Teramoto T, Shimano H, Yokote K, Urashima M. New evidence on pitavastatin: Efficacy and safety in clinical studies. Expert Opin Pharmacother 2010; 11(5): 817-28.
[http://dx.doi.org/10.1517/14656561003641990] [PMID: 20201733]
[33]
Wang N, Fulcher J, Abeysuriya N, et al. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: A systematic review and meta-analysis of randomised trials including 327 037 participants. Lancet Diabetes Endocrinol 2020; 8(1): 36-49.
[http://dx.doi.org/10.1016/S2213-8587(19)30388-2] [PMID: 31862150]
[34]
Grinspoon SK, Fitch KV, Overton ET, et al. Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). Am Heart J 2019; 212: 23-35.
[http://dx.doi.org/10.1016/j.ahj.2018.12.016] [PMID: 30928825]

Rights & Permissions Print Cite
Article Metrics
74
2
© 2024 Bentham Science Publishers | Privacy Policy